Mesalazin Orion (Mesalazine)

Mesalazine inhibits cyclooxygenase and lipoxygenase pathways within the intestinal mucosa, lowering the production of prostaglandins and leukotrienes. This local anti‑inflammatory action reduces activation of inflammatory cells and cytokine release, thereby decreasing mucosal inflammation without substantial systemic absorption.

The appropriate dose of Mesalazin Orion is individualized by the prescribing healthcare professional based on the severity of disease, patient weight, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To request Mesalazin Orion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mesalazin Orion is a locally acting Aminosalicylate, whereas alternatives such as sulfasalazine also contain a sulfapyridine moiety that can cause additional side effects. Biologic agents target systemic immune pathways and are reserved for moderate‑to‑severe disease. Mesalazine is often preferred for mild‑to‑moderate disease because of its targeted action and favorable safety profile.

Store Mesalazin Orion at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Mesalazin Orion is taken orally, usually with water. The tablets or capsules should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional. Dosing frequency and timing are determined by the prescriber.

Serious adverse events, although rare, include myocarditis, pericarditis, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should seek immediate medical attention if they experience chest pain, unexplained fever, rash, blistering, or signs of organ involvement.

Mesalazin Orion should be avoided in individuals with known hypersensitivity to mesalazine or any component of the formulation. Caution is also advised for patients with severe renal impairment, active cardiac disease, or those who have previously experienced severe allergic reactions to Aminosalicylates.